The short version of Heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-06 and is reviewed periodically as new material appears.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
=== Waffle and Steak === For years, Waffle House was known as "Waffle and Steak" in Indiana due to another chain of restaurants owning the rights to the Waffle House name in the state. The original Indiana Waffle House chain has started using the name "Sunshine Cafe". However, the d/b/a for "Sunshine Cafe" belongs to "Waffle House Greenwood Inc.", established in 1981. The oldest "Waffle House" entity listed with the Corporations office of the Indiana Secretary of State is "Waffle House of Bloomington, Indiana, Inc." established in 1967, and, like Waffle House Greenwood, it is still an active corporation. The Bloomington operation, the city's second oldest restaurant, closed in 2013, and was demolished to make way for an apartment complex. (Many of the Waffle House corporations in Indiana have been dissolved.) "Waffle House Inc." of Norcross, Georgia, registered with Indiana in 1974. In 2005, the Waffle and Steak restaurants all adopted the "Waffle House" moniker, bringing the entire chain under the name.
=== Physical === Cardiovascular side effects can include hypotension (including orthostatic hypotension) and bradycardia; atrioventricular block and other bradyarrhythmias have also been reported. Raynaud's phenomenon and syncope may also occur. Because clonidine can cause bradycardia and hypotension, precautions are advised in people with sinoatrial node dysfunction (e.g., sick sinus syndrome) or atrioventricular block, and in those with severe coronary artery disease, cerebrovascular disease, or chronic kidney failure. Gastrointestinal side effects can include xerostomia, constipation, nausea, and vomiting. Colonic pseudo-obstruction has been described as a rare side effect. Other reported physical side effects include headache, fatigue or weakness and, less commonly, urinary retention and transient edema. In addition to dry mouth, clonidine has been reported to reduce tear production (i.e., dry eyes), a rare side effect that may be more noticeable in people who wear contact lenses. Skin reactions can occur with transdermal formulations of clonidine; contact dermatitis at the transdermal patch application site has been reported in about 15% to 20% of users.
For example, "Strep throat" is often diagnosed within minutes, and is based on the appearance of antigens made by the causative agent, S. pyogenes, that is retrieved from a patient's throat with a cotton swab. Serological tests, if available, are usually the preferred route of identification, however the tests are costly to develop and the reagents used in the test often require refrigeration. Some serological methods are extremely costly, although when commonly used, such as with the "strep test", they can be inexpensive. Complex serological techniques have been developed into what are known as immunoassays. Immunoassays can use the basic antibody–antigen binding as the basis to produce an electro-magnetic or particle radiation signal, which can be detected by some form of instrumentation. Signal of unknowns can be compared to that of standards allowing quantitation of the target antigen. To aid in the diagnosis of infectious diseases, immunoassays can detect or measure antigens from either infectious agents or proteins generated by an infected organism in response to a foreign agent. For example, immunoassay A may detect the presence of a surface protein from a virus particle. Immunoassay B on the other hand may detect or measure antibodies produced by an organism's immune system that are made to neutralize and allow the destruction of the virus. Instrumentation can be used to read extremely small signals created by secondary reactions linked to the antibody – antigen binding.
=== 3 June === A missile strike on Dnipro killed a two-year-old girl and wounded 22 people after it hit a two-story building. Five of them were reportedly children, seventeen people were hospitalized and several were believed to have been trapped under the rubble. Belgorod Oblast Governor Vyacheslav Gladkov said that two people were killed by Ukrainian shelling.
Sources: en.wikipedia.org
=== Cocaine === Carlezon et al. performed several experiments to validate this model. They found that, when mice were injected with cocaine, they preferred to be in the place where they were injected (showed stronger place preference) significantly more than control mice (injected with saline) did. However, in mice overexpressing CREB under a constitutive promoter, place aversion was observed. This indicates that increasing CREB reverses the positive effects of cocaine. Northern blot analysis several days after CREB overexpression showed a marked increase in dynorphin mRNA in the nucleus accumbens. Blocking KORs with an antagonist (nor-BNI) blocked the aversive effects caused by CREB overexpression. Thus, cocaine use ultimately appears to lead to an increase in the transcription of prodynorphin mRNA. Dynorphin inhibits dopamine release, which could account the reinforcing properties of cocaine. There is also evidence suggesting that increased amounts of dynorphin can protect humans from cocaine addiction. According to research at Rockefeller University, the gene for dynorphin is present in two versions: a “high output” and a “low output” functional variation. The high output functional variation of the gene contains polymorphisms in the promoter regions that are speculated to cause it to produce more copies of dynorphin mRNA, which would give people carrying this variation a “built-in defense system” against drug addiction.
RO5203648 suppressed spontaneous hyperactivity in a novel environment in dopamine transporter (DAT) knockout mice, similarly to antipsychotics like haloperidol and olanzapine. RO5203648 has also been found to suppress hyperlocomotion induced by the NMDA receptor antagonist L-687,414 or in genetically modified mice with a hypoactive NMDA receptor. The effects of RO5203648 on hyperdopaminergic- and hypoglutamatergic-mediated hyperlocomotion are similar to those of the TAAR1 full agonist RO5166017. The drug has shown anti-cataleptic, pro-cognitive, antipsychotic-like, antidepressant-like, anxiolytic-like, anti-addictive, and wakefulness-promoting effects in animals. RO5203648, as well as the TAAR1 full agonist RO5256390, have been found to suppress cocaine and methamphetamine self-administration, and hence presumably their rewarding and reinforcing effects. RO5203648 also blocked methamphetamine-induced locomotor sensitization, but cross-sensitized with methamphetamine at the highest dose. RO5203648 by itself is not self-administered in animals, suggesting that it lacks reinforcing effects and misuse liability of its own.
The DSM-5 characterizes diagnosis under several categories—mild, moderate, severe, and extreme—each determined by the number of binges the patient exhibits per week. Mild: 1–3 episodes per week, Moderate: 4–7 episodes per week, Severe: 8–13 episodes per week, Extreme: 14 or more episodes per week Further, the remission states are classified under the following. Partial Remission: Following a previous diagnosis, the average frequency of binge eating episodes decreases to less than one episode per week for a sustained period. Full Remission: Following a previous diagnosis, none of the criteria have been met for a sustained period.
The organization of solvent systems into "families" has greatly facilitated the choice of solvent systems as well. A solvent system can be tested with a one-flask partitioning experiment. The measured partition coefficient from the partitioning experiment will indicate the elution behavior of the compound. Typically, it is desirable to choose a solvent system where the target compound(s) have a partition coefficient between 0.25 and 8. Historically, it was thought that no commercial countercurrent chromatograph could cope with the high viscosities of ionic liquids. However, modern instruments that can accommodate 30 to 70+ % ionic liquids (and potentially 100% ionic liquid, if both phases are suitably customized ionic liquids) have become available. Ionic liquids can be customized for polar / non-polar organic, achiral and chiral compounds, bio-molecule, and inorganic separations, as ionic liquids can be customized to have extraordinary solvency and specificity. After the biphasic solvent system has been chosen a batch of is formulated and equilibrated in a separatory funnel. This step is called pre-equilibration of the solvent system. The two phases are separated. Then the column is filled with stationary with a pump. Next, the column is set an equilibration conditions, such as the desired rotation speed, and the mobile phase is pumped through the column. The mobile phase displaces the a portion of the stationary phase until column equilibration is achieved and the mobile phase elutes from the column.
Communication between networks of the Moroccan mafia was mostly exercised by the use of Blackberry smartphone messaging equipped with PGP technology. On 19 April 2016, the Canadian authorities intervened a hosting company with the aim of decrypting the Dutch telecommunication servers of Ennetcom. The servers contained millions of messages that were sent through Ennetcom. The cybercrime investigators of the Netherlands Forensic Institute finally managed to decrypt the messages in Canada. When the messages were deciphered, the investigators found out that the messages were all written in Tarifit, a language that was unknown to them. The names of the criminals were also replaced by nicknames. Between 2016 and 2018, the Dutch police forces investigated the nicknames to identify commanders as well as contract killers. Following the dismantling of the Ennetcom network, several criminal organisations have converted to the use of other encrypted communication services. Some criminals, including Saïd Razzouki, have been avoiding to communicate through electronic devices. Because of this, Razzouki could operate unknowingly for over 8 years before being arrested in Medellín by the DEA and FBI. Commanders or crime bosses are rarely found in Europe. They often stay hidden under the radar in places like Morocco, Latin-America, Arab states of the Persian Gulf, and Thailand.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.